Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double Blinded, Multicentre Phase II Study to Assess the Efficacy of Olaparib (AZD2281, KU-0059436) in Combination With Paclitaxel Versus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy

NCT01063517 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01063517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01063517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double Blinded, Multicentre Phase II Study to Assess the Efficacy of Olaparib (AZD2281, KU-0059436) in Combination With Paclitaxel Versus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
February 2, 2010
Completion date
June 29, 2023
Enrollment
124 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer